Solventum Corporation (SOLV)

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification...

SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.

Solventum Corporation (NYSE:SOLV ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communic...

Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street...

Solventum (SOLV) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.56 per share a year ago.

Solventum (SOLV) Fiscal Q2 EPS Jumps 8%

Medical device maker Solventum raised full-year adjusted profit forecast on Thursday, driven by strong sales of its wound care and surgical sterilization products alongside lower expenses.

SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.

Beyond analysts' top-and-bottom-line estimates for Solventum (SOLV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte...

Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure fro...